| Catalog No. |
TD-VK515056 |
| Description |
Lesofavumab is a recombinant monoclonal antibody to Influenza B virus hemagglutinin. Lesofavumab is a human monoclonal antibody that can be potentially used in the treatment of Influenza B infection. Genentech, a subsidiary of Roche, is developing Lesofavumab (RG6024), a monoclonal antibody, for the treatment of influenza B infections. |
| Species reactivity |
Influenza B virus |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG1, kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
HA/Hemagglutinin |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P03461 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
RG6024,RG6024,MHAB5553A,RG70026,RO7045557,CAS:1807960-57-1 |
| Background |
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |